MRI Guided SBRT for Localized Prostate Cancer

Running, not enrolling · Not applicable

Conditions studied: Prostate Cancer

In brief

This study utilizes advanced imaging techniques (mpMRI prostate scan) to select and stratify patients for two different radiotherapy regimens based on the presence/absence of identifiable intraprostatic lesions. In patients without identifiable prostate cancer lesions, SBRT to the prostate in 5 sessions (fractions) will be administered. In patients with MRI-identified lesion(s), pelvic IMRT in 25 fractions will be administered followed by an SBRT prostate boost while simultaneously treating the prostate cancer lesion(s) to a higher dose in 3 fractions.

Key facts

Study ID

NCT03778112

Run by

Rush University Medical Center

People needed

54

Starts

2016-05-23

Expected to finish

2029-03-01

Last updated by the study team

2026-03-09

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Biopsy proven prostate adenocarcinoma within 1 year of randomization
• NCCN Low to High Risk localized prostate cancer
• Zubrod Performance Status 0-1 within 60 days prior to registration

You may not qualify if…

• Prior or concurrent invasive malignancy (except non-melanoma skin cancer)
• Regional Lymph Node (N1) involvement
• Distant Metastases (M1) involvement
• History of prior pelvic irradiation (external beam radiotherapy or brachytherapy)
• Prior chemotherapy
• Severe, active co-morbidities (unstable angina and/or CHF; MI; COPD; liver disease; AIDS)
• Acute bacterial or fungal infection requiring IV antibiotics
• Inability to undergo MRI
• Inability to receive fiducial markers

Where it is running

• Rush University Medical Center — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.